The experiments
PT-141 research in women, men and animals
The development story narrows as it goes: broad early sexual-function research, then trials in women distressed by low desire.
PT-141 for women
The pivotal population was premenopausal women with acquired, generalized HSDD. Their low desire caused distress, had developed after previously normal desire, and extended across situations. The two matching Phase 3 RECONNECT trials enrolled 1,267 women and compared as-needed subcutaneous bremelanotide with placebo over 24 weeks. Subcutaneous means beneath the skin.
The study gave 1.75 mg. That is a description of the trial, with the dose-finding history behind it. In June 2019, bremelanotide injection received FDA approval for this defined condition. The first-approval review follows the transition into medicine.
PT-141 benefits in RECONNECT
The integrated difference from placebo was +0.35 on the FSFI desire score and -0.33 on FSDS-DAO item 13, the item about distress over low desire. Both results had P<.001 in the published Phase 3 analysis. Those questionnaire names matter because desire and distress were the outcomes being measured; the figures express differences in questionnaire scores.
That distress was worth investigating; on this point I applaud the program. Sweeping descriptions of sexual transformation lose me at these modest score changes. The controversy over clinical meaningfulness is understandable: statistical confidence in a difference and the value of that difference in everyday life are separate judgments.
The earlier responder analysis asks how many women crossed a threshold for meaningful improvement. That question gets closer to the practical issue: how often was a change large enough to matter in someone's life?
The extension cohort
A 52-week open-label extension enrolled 684 women. Open-label means they knew which treatment they received. The report describes sustained desire improvements and no new safety signals, alongside nausea, flushing and headache.
For following tolerability longer, I credit the extension. Knowledge of treatment and the absence of the original blinded comparison also shape what can be concluded about continuing benefit. The exact symptom frequencies appear on side effects.
PT-141 for men
The early male studies asked about erections. A nasal-spray study in healthy men and men with erectile dysfunction reported a dose-dependent response, with a statistically significant erectile response above 7 mg and first erections at roughly 30 minutes. A separate subcutaneous study included men inadequately helped by sildenafil. Another study examined PT-141 combined with sildenafil.
These belong to the early development record. The approved indication remains premenopausal HSDD in women; PT-141 for men and for erectile dysfunction has no FDA approval.
PT-141 mechanism of action
Bremelanotide activates central melanocortin receptors, particularly MC4R and secondarily MC3R. These sit in hypothalamic and limbic pathways involved in motivation; dopamine signaling is thought to contribute to the sexual effects. The early mechanism paper connects animal behavior, brain-cell activity and early human responses. Sildenafil acts on vascular smooth muscle to support erectile blood flow, which explains why the combination research was an interesting pharmacological question.
In a crossover study of 31 premenopausal women with HSDD, each woman received drug and placebo at different times. The brain-imaging experiment found higher reported desire for up to 24 hours, together with altered brain processing of erotic stimuli. The amygdala and insula showed more closely coordinated activity. A scan makes the central action more tangible, though the women still had to report how desire felt.
Rat behavior and hamster reward
In female rats studied in 2004, PT-141 increased sexual solicitation—the approaches that initiate an encounter—while lordosis, pacing and general movement were unchanged. In female Syrian hamsters studied in 2025, bremelanotide did not enhance sexual reward in a conditioned-place-preference test. That test asks whether an animal favors a place associated with a rewarding experience.
I enjoy this wrinkle because it makes the story more precise. Solicitation in rats and place preference in hamsters ask different questions about sexual behavior. The hamster result leaves room for a central effect on motivation while making a simple claim of enhanced reward harder to defend. Both findings belong to animal research.